Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy

References

• Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30:2212–2219.
   PubMed Web of Science ®Google Scholar
• Liaw YF. Antiviral therapy of chronic hepatitis B: opportunities and challenges in Asia. J Hepatol. 2009;51:403–410.
   PubMed Web of Science ®Google Scholar
• Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.
   PubMed Web of Science ®Google Scholar
• Chien J, Liu J, Lee MH, et al. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis. J Gastroenterol Hepatol. 2016;31:1971–1977.
   PubMed Web of Science ®Google Scholar
• Lee MH, Yang HI, Liu J, et al. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 2013;58:546–554.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Lau GK, Kao JH, et al. Hepatitis B e antigen seroconversion: a critical event in chronic hepatitis B virus infection. Dig Dis Sci. 2010;55:2727–2734.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Kim HS, Kim HJ, Shin WG, et al. Predictive factors for early HBeAg seroconversion in acute exacerbation of patients with HBeAg-positive chronic hepatitis B. Gastroenterology. 2009;136:505–512.
   PubMed Web of Science ®Google Scholar
• Vlachogiannakos J, Papatheodoridis GV. Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients? Liver Int. 2015;35(Suppl 1):100–106.
   PubMed Web of Science ®Google Scholar
• Lin B, Ha NB, Liu A, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013;28:855–860.
   PubMedGoogle Scholar
• Lau GK. Current treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversion. Liver Int. 2010;30:512–520.
   PubMed Web of Science ®Google Scholar
• Woo ASJ, Kwok R, Ahmed T. Alpha-interferon treatment in hepatitis B. Ann Transl Med. 2017;5:159
   PubMed Web of Science ®Google Scholar
• Song G, Rao H, Feng B, et al. Prediction of spontaneous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients during the immune clearance phase. J Med Virol. 2014;86:1838–1844.
   PubMed Web of Science ®Google Scholar
• Mak LY, Wong DK, Cheung KS, et al. Hepatitis B core-related antigen (HBcrAg): an emerging marker for chronic hepatitis B virus infection. Aliment Pharmacol Ther. 2018;47:43–54.
   PubMed Web of Science ®Google Scholar
• Lin CL, Kao JH. New perspectives of biomarkers for the management of chronic hepatitis B. Clin Mol Hepatol. 2016;22:423–431.
   PubMed Web of Science ®Google Scholar
• Chen EQ, Feng S, Wang ML, et al. Serum hepatitis B core-related antigen is a satisfactory surrogate marker of intrahepatic covalently closed circular DNA in chronic hepatitis B. Sci Rep. 2017;7:173.
   PubMed Web of Science ®Google Scholar
• Matsumoto A. Hepatitis B core-related antigen: a strong indicator for cessation of nucleos(t)ide analog therapy in patients with chronic hepatitis B. J Gastroenterol. 2017;52:127–128.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Asselah T, Marcellin P. HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients. Liver Int. 2015;35(Suppl 1):82–90.
   PubMed Web of Science ®Google Scholar
• Xiong YL, Li H, Liu F, et al. Efficacy of PEGylated interferon in treatment-experienced Chinese patients with HBeAg positive chronic hepatitis B. Hepat Mon. 2016;16:e35357.
   PubMed Web of Science ®Google Scholar
• Kao JH. HBeAg-positive chronic hepatitis B: why do I treat my patients with pegylated interferon? Liver Int. 2014;34(Suppl 1):112–119.
   PubMed Web of Science ®Google Scholar
• Chuaypen N, Posuwan N, Payungporn S, et al. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B. Liver Int. 2016;36:827–836.
   PubMed Web of Science ®Google Scholar
• Janssen HL, Sonneveld MJ, Brunetto MR. Quantification of serum hepatitis B surface antigen: is it useful for the management of chronic hepatitis B? Gut 2012;61:641–645.
   PubMed Web of Science ®Google Scholar
• Cheung KS, Seto WK, Wong DK, et al. Relationship between HBsAg, HBcrAg and hepatocellular carcinoma in patients with undetectable HBV DNA under nucleos(t)ide therapy. J Viral Hepat. 2017;24:654–661.
   PubMed Web of Science ®Google Scholar
• Ma H, Yang RF, Li XH, et al. HBcrAg identifies patients failing to achieve HBeAg seroconversion treated with pegylated interferon alfa-2b. Chin Med J (Engl). 2016;129:2212–2219.
   PubMed Web of Science ®Google Scholar
• Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis. 2016;20:645–665.
   PubMed Web of Science ®Google Scholar
• Rajoriya N, Combet C, Zoulim F, et al. How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach? J Hepatol. 2017;67:1281–1297.
   PubMed Web of Science ®Google Scholar
• Tian Q, Jia J. Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia. Hepatol Int. 2016;10:854–860.
   PubMed Web of Science ®Google Scholar
• Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther. 2008;13:211–220.
   PubMed Web of Science ®Google Scholar